Study for lipid metabolism and atherosclerosis using antisense oligodeoxy nucleotides targeted to liver

使用靶向肝脏的反义寡脱氧核苷酸研究脂质代谢和动脉粥样硬化

基本信息

  • 批准号:
    09670727
  • 负责人:
  • 金额:
    $ 2.05万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1998
  • 项目状态:
    已结题

项目摘要

Effect of Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol -fed RabbitsIn the present study, we examined the effect of the suppression of increased plasma CETP by intravenous injection with antisense oligodeoxynucleotides (ODNs) against CETP targeted to the liver on the development of atherosclerosis in rabbits fed a cholesterol diet. ASOR-poly (L) lysine-ODNs cornplex were injected via The ear veins twice a week. The total cholesterol concentrations and the CETP mass in the animals injected with antisense ODNs were all significantly decreased in 12 and 16 weeks compared with those injected with sense ODNs and the control animals. When the HDL cholesterol concentrations were measured after the isolation by ultracentrifugation and a column chromotography, they were significantly higher in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals. A reduct … More ion of CETP mRNA and an increase of LDL-R mRNA in the liver were observed in the animals injected with antisense ODNs compared with those injected with sense ODNs and the control animals. Aortic cholesterol contents and the aortic percentage lesion to total surface area were significantly lower in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals.Secretion of prebeta HDL increases with the suppression of cholesteryl ester transfer protein in Hep G2 cells In the present stud we examined the effect of the suppression of hepatic CETP by antisense oligodeoxynucleotides (ODNs) against CETP targeted to the liver on the secretion of apo A-I using a Hep G2 cell culture. The control group received saline, while the sense group was mixed with the sense ODN s complex and the antisense group was mixed with the antisense ODNs complex, respectively, for 2 days. Both the hepatic CETP mRNA and the CETP mass in the medium in the antisense group decreased significantly more than in the sense and the control groups. In contrast, both the hepatic a p o A-I mRNA and the apo A-l mass in the medium in the antisense group were significantly higher than those in the sense and the control groups. The increase in apo A-l was mainly due to the increase in prebeta apo A-I.Effects of Reduced Plasma Angiotensinogen by Antisense Oligodeoxynucleotides on Vascular Remodeling in Spontaneously Hypertensive RatsIn the present study, we examined the effect of the suppression of plasma AGT by intravenous injection with antisense oligodeoxynucleotides (ODNs) against AGT targeted to the liver on the vascular remodeling in spontaneously hypertensive rats ( SHR ). At 1 0 weeks of age, SHR were divided into 3 groups ( six animals in each group ), among which the systolic blood pressure (BP) did not significantly change. The control group received saline, the sense group were injected with the sense ODNs complex and the antisense group were injected with the antisense ODNs complex, respectively, from 10 to 20 weeks of age. WKY rats were fed for the same period of time. ASOR-poly(L)lysine-ODNs complex were injected via the tail veins twice a week. At the end of the treatment, a reduction of AGT mRNA in the liver and plasma AGT were observed only in the animals injected with antisense ODNs compared with the other groups of SHR and WKY rats. Antisense ODNs were found to have significantly reduced the plasma angiotensin II (Ang II) concentration to the level of WKY rats. Antisense ODNs significantly reduced BP and media cross-sectionaI area of the aorta, which were still larger than WKY rats, in comparison to the SHR injected with sense ODNs and control SHR.The aortic angiotensin converting enzyme (ACE) activity and collagen concentration, which was significantly higher than those in WKY rats, did not significantly change among the groups of SHR.The aortic AGT, ACE, angiotensin type 1 (AT1) receptor and angiotensin type 2(AT2) receptor mRNA did not significantly change either among the groups of SHR. Less
针对胆固醇酯转运蛋白的反义寡核苷酸对高脂饮食兔动脉粥样硬化形成的影响本研究通过静脉注射针对肝脏的针对CETP的反义寡核苷酸来抑制高脂饮食兔血浆CETP的升高,探讨其对高脂饮食兔动脉粥样硬化形成的影响。每周两次耳缘静脉注射ASOR-聚(L)赖氨酸-寡核苷酸复合体。在12周和16周,注射反义ODN的动物的总胆固醇浓度和CETP质量均显著低于注射正义ODN的动物和对照组。超速离心和柱层析分离后测定高密度脂蛋白胆固醇浓度时,注射反义寡核苷酸的动物的高密度脂蛋白浓度显著高于注射正义寡核苷酸的动物和对照组。A Reduct…注射反义ODN组大鼠肝脏CETP基因表达明显高于正义ODN组和对照组,肝组织低密度脂蛋白受体基因表达明显高于正义ODN组和对照组。注射反义ODN的动物的主动脉胆固醇含量和病变占总表面积的百分比明显低于注射正义ODN的动物和对照组动物。Hep G2细胞分泌前β-高密度脂蛋白随着胆固醇酯转运蛋白的抑制而增加。本研究采用Hep G2细胞培养方法,观察了针对CETP的反义寡核苷酸抑制肝脏CETP对载脂蛋白A-I分泌的影响。对照组给予生理盐水,正义组加入正义寡核苷酸S复合体,反义组加入反义寡核苷酸复合体,共2d。反义组大鼠肝脏CETP mRNA和培养液中CETP质量下降幅度均明显大于正义组和对照组。反义寡核苷酸组大鼠肝细胞膜载脂蛋白A-IMRNA和载脂蛋白A-L质量均显著高于正义组和对照组。载脂蛋白A-L的升高主要是由于载脂蛋白A-I的增加,反义寡核苷酸降低血浆血管紧张素原水平对自发性高血压大鼠血管重构的影响本研究观察了静脉注射针对肝组织血管紧张素原的反义寡核苷酸抑制自发性高血压大鼠血管重构的作用。10周龄时,SHR分为3组,每组6只,其中收缩压无明显变化。10~20周龄,对照组注射生理盐水,正义组注射正义寡核苷酸复合体,反义组注射反义寡核苷酸复合体。WKY大鼠饲喂相同时间。尾静脉注射ASOR-多(L)赖氨酸-寡核苷酸复合体,每周2次。治疗结束时,与SHR和WKY大鼠相比,仅注射反义ODN的大鼠肝组织AGT mRNA和血浆AGT表达下降。反义寡核苷酸显著降低血浆血管紧张素II(Ang II)浓度至WKY大鼠水平。与SHR组和对照SHR组相比,反义ODN显著降低了SHR大鼠的血压和主动脉中膜横截面积,但仍大于WKY大鼠。SHR组大鼠的主动脉血管紧张素转换酶(ACE)活性和胶原浓度显著高于WKY组大鼠,而血管紧张素转换酶(ACE)、血管紧张素转换酶(AT1)受体和血管紧张素受体2(AT2)受体的mRNA在SHR组之间也没有明显变化。较少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Otsuka S,Sugano M,Makino N,Sawada S,Hata T,Niho Y.: "Interaction of mRNAs for Angiotensin II Type 1 and Type 2 Receptors to Vascular Remodelling in Spontaneously Hypertensive Rats"Hypertension.. 32. 467-472 (1998)
Otsuka S、Sugano M、Makino N、Sawada S、Hata T、Niho Y.:“血管紧张素 II 1 型和 2 型受体 mRNA 与自发性高血压大鼠血管重塑的相互作用”高血压.. 32. 467-472 (1998)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Sawada S,Sugano M,Makino N,Okamoto H,tsuchida K.: "Secretion of prebeta HDL increases with the suppression of cholesteryl ester transfer protein in Hep G2 cells." Atherosclerosis. (in press).
Sawada S、Sugano M、Makino N、Okamoto H、tsuchida K.:“随着 Hep G2 细胞中胆固醇酯转移蛋白的抑制,前β HDL 的分泌增加。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Makino N,Sugano M,Otsuka S,Hata T.: "Molecular Mechanism of Angiotensin II Type I and Type II Receptors in Cardiac Hypertrophy of Spontaneously Hypertensivr Rats." Hypertension. 30. 796-802 (1997)
Makino N,Sugano M,Otsuka S,Hata T.:“血管紧张素 II I 型和 II 型受体在自发性高血压大鼠心脏肥大中的分子机制。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
T.Komura, K.Takahara, M.Sugano, A.Fujinishi, H.Tasaki, Y.Nakashima, A.Kuroiwa: "Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol." Eur.J.Pharmacokine. 22 (3). 201-206 (1997)
T.Komura、K.Takahara、M.Sugano、A.Fujinishi、H.Tasaki、Y.Nakashima、A.Kuroiwa:“低密度脂蛋白血浆分离术对亲脂性抗血脂剂普罗布考药代动力学的影响”。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Masahiro Sugano,Naoki Makino,Takashi Yanaga: "Effect of Dietary Omega-3 Eicosapentaenoic acid Supplements on Cholesteryl ester Transfer from HDL in Cholesterol-fed Rabbits" Biochimica et Biophysica Acta. 1346. 17-24 (1997)
Masahiro Sugano、Naoki Makino、Takashi Yanaga:“膳食 Omega-3 二十碳五烯酸补充剂对胆固醇喂养兔子中 HDL 胆固醇酯转移的影响”Biochimica et Biophysicala Acta。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUGANO Masahiro其他文献

SUGANO Masahiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUGANO Masahiro', 18)}}的其他基金

Effect of siRNA targeting SHP-1 on angiogenesis in hindlimb ischemia
靶向SHP-1的siRNA对后肢缺血血管生成的影响
  • 批准号:
    18590817
  • 财政年份:
    2006
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Therapy for ischemic vascular diseases using soluble TNF-alpha receptor 1 gene
利用可溶性TNF-α受体1基因治疗缺血性血管疾病
  • 批准号:
    14570671
  • 财政年份:
    2002
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of new gene therapy for treatment of atherosclerosis using anti-apoptotic genes
开发利用抗凋亡基因治疗动脉粥样硬化的新基因疗法
  • 批准号:
    12670678
  • 财政年份:
    2000
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

肝受体类似物(Liver Receptor Homolog 1, LRH 1)在雌鼠生殖过程中的作用及其机制
  • 批准号:
    31172040
  • 批准年份:
    2011
  • 资助金额:
    59.0 万元
  • 项目类别:
    面上项目

相似海外基金

HoloSurge: Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers
HoloSurge:多模态 3D 全息工具和实时指导系统,具有护理点诊断功能,可用于肝癌和胰腺癌的手术规划和干预
  • 批准号:
    10103131
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    EU-Funded
GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
Atypical Chemokine Receptors orchestrate changes in vascular patterning during fibrotic liver disease via Endothelial-to-Mesenchymal Transition.
非典型趋化因子受体通过内皮-间质转化协调纤维化肝病期间血管模式的变化。
  • 批准号:
    MR/Y013751/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
Investigation of Endocrine-Disrupting Chemicals as Contributors to Progression of Metabolic Dysfunction Associated Steatotic Liver Disease (EDC-MASLD)
内分泌干​​扰化学物质对代谢功能障碍相关脂肪性肝病 (EDC-MASLD) 进展的影响的调查
  • 批准号:
    10092670
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    EU-Funded
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
  • 批准号:
    10087822
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    EU-Funded
AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients (Artemis)
加速虚拟双胞胎向脂肪肝患者个性化管理的转化(Artemis)
  • 批准号:
    10109933
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    EU-Funded
HoloSurge:Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers
HoloSurge:多模态 3D 全息工具和实时引导系统,具有护理点诊断功能,可用于肝癌和胰腺癌的手术规划和干预
  • 批准号:
    10109943
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    EU-Funded
Pluripotent stem cell derived hepatocytes for liver failure (PUSH for LIFE)
多能干细胞衍生的肝细胞治疗肝衰竭(PUSH for LIFE)
  • 批准号:
    MR/Z503940/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
Multi-modal non-invasive biomarker screening for high-risk undiagnosed liver disease
针对高危未确诊肝病的多模式非侵入性生物标志物筛查
  • 批准号:
    10073169
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Collaborative R&D
Quantitative ultrasound to improve detection and diagnosis of liver cancer
定量超声改善肝癌的检测和诊断
  • 批准号:
    490038
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了